m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02398)
Name
Suramin
Synonyms
Antrypol; Belganyl; Farma; Fourneau; Germanin; Moranyl; Naganil; Naganin; Naganine; Naganol; Naphuride; SVR; Suramine; SURAMIN SODIUM; Sodium suramin; Suramine sodium; Farma 939; Naganol 6 Na; Germanin (TN); SGCTO-001
    Click to Show/Hide
Status
Phase 1
Structure
3D MOL
2D MOL
Formula
C51H40N6O23S6
InChI
1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)
InChIKey
FIAFUQMPZJWCLV-UHFFFAOYSA-N
PubChem CID
5361
TTD Drug ID
D0H2UB
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Follicle-stimulating hormone receptor (FSHR)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Follicle-stimulating hormone receptor (FSHR) is a therapeutic target for Suramin. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Suramin through regulating the expression of Follicle-stimulating hormone receptor (FSHR). [1], [2]
Heparanase (HPSE)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Heparanase (HPSE) is a therapeutic target for Suramin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Suramin through regulating the expression of Heparanase (HPSE). [3], [4]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253).
Ref 3 Insulin-like growth factor 2 mRNA binding protein 2 regulates proliferation, migration, and angiogenesis of keratinocytes by modulating heparanase stability. Bioengineered. 2021 Dec;12(2):11267-11276. doi: 10.1080/21655979.2021.2002495.
Ref 4 Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost. 2006 Mar;4(3):560-5. doi: 10.1111/j.1538-7836.2006.01792.x.